Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hepatic and vascular enhancement a at dual-phase helical CT: comparison oflobitridol 300 and lohexol 300 in a prospective randomized study
Autore:
Legmann, P; Vignaux, O; Bahurel, H; Coste, J; Oudjit, A;
Indirizzi:
Univ Paris 05, Hop Cochin, Dept Radiol, F-75014 Paris, France Univ Paris 05 Paris France F-75014 n, Dept Radiol, F-75014 Paris, France Univ Paris 05, Dept Biostat & Epidemiol, Hop Cochin, F-75014 Paris, FranceUniv Paris 05 Paris France F-75014 ol, Hop Cochin, F-75014 Paris, France
Titolo Testata:
EUROPEAN RADIOLOGY
fascicolo: 11, volume: 11, anno: 2001,
pagine: 2220 - 2227
SICI:
0938-7994(2001)11:11<2220:HAVEAA>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
OSMOLALITY CONTRAST-MEDIA; INJECTION PROTOCOL; IOBITRIDOL XENETIX; CLINICAL TOLERANCE; EFFICACY; SAFETY; IOHEXOL; LIVER; ANGIOGRAPHY; BOLUS;
Keywords:
contrast medium; helical CT; time-density curve; clinical tolerance; image quality;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Legmann, P Univ Paris 05, Hop Cochin, Dept Radiol, 27 Rue Faubourg St Jacques, F-75014 Paris, France Univ Paris 05 27 Rue Faubourg St Jacques Paris France F-75014
Citazione:
P. Legmann et al., "Hepatic and vascular enhancement a at dual-phase helical CT: comparison oflobitridol 300 and lohexol 300 in a prospective randomized study", EUR RADIOL, 11(11), 2001, pp. 2220-2227

Abstract

The purpose of this study was to determine hepatic and vascular enhancement, clinical tolerance, and iconographic quality of Iobitridol (300 mg/ml) at dual-phase helical CT and to compare it with Iohexol (300 mg/ml). One hundred forty-six patients were randomly divided into two groups. Each group received 120 ml of Iohexol (group A) or Iobitridol (group B). Mean enhancement of liver, aorta and portal vein was obtained at the arterial phase and at the portal-venous phase. Overall image quality was assessed by two independent blinded investigators. Adverse reactions were recorded. There were nosignificant differences in demographic characteristics and distribution ofpatient intrinsic parameters between the two groups, except for blood pressure but without statistical correlation between the difference in blood pressure and the impact on enhancement measurements. There was no significantdifference in clinical tolerance and image quality. Mean liver as well as aortic and portal vein enhancement measurements did not show any significant difference. Iobitridol compares favorably with Iohexol. Both products have similar safety, tolerance, and efficacy. Both contrast media have equivalent blood pool concentration and interstitial compartment diffusion.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 11:44:44